Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Total Current Liabilities
All obligations due within one year.
Septerna, Inc.NASDAQ: SEPN
Total Current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total current liabilities rises 39.3% from a year ago
Total current liabilities stood at $104.86M at the end of Q3 FY2026, up 39.3% from a year earlier and up 32.2% from the prior quarter. Over 3 fiscal years it compounded at +150.3% a year.
Context
- Total current liabilities amounted to 16.9% of total assets at the end of Q3 FY2026, up 4.5 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +39.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 86.93M USD
- Year-over-year change
- +576.6%
- 3-year CAGR
- +150.3%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 86.93M | +576.6% |
| FY2024 | 2024-12-31 | 12.85M | +85.8% |
| FY2023 | 2023-12-31 | 6.91M | +24.7% |
| FY2022 | 2022-12-31 | 5.54M | — |
Total Current Liabilities vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's Sep 2026 total current liabilities of $104.86M is the highest of the 7 companies compared; the peer median is $23.2M.
- Its year-over-year change of +39.3% is the 4th highest of 6, against a peer median of +59.4%.
- Total current liabilities amounts to 16.9% of total assets for SEPN, versus a peer median of 6.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
SEPNSepterna, Inc. | Sep 2026 | $104.86M | +39.3% | +150.3% | 16.9% |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $83.65M | — | — | 6.9% |
| Jun 2026 | $66.11M | +69.4% | +69.4% | 4.6% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $25.17M | +108.6% | +65.3% | 5.0% |
| Mar 2026 | $21.24M | +14.1% | +2.8% | 5.1% | |
| Mar 2026 | $9.29M | -53.1% | -16.5% | 20.0% | |
| Mar 2026 | $6.88M | +59.4% | -4.8% | 7.0% | |
| Peer median (excluding SEPN) | $23.2M | +59.4% | +2.8% | 6.0% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.